Fundraising Fox
Succipro
1 known investors
Find your way into Succipro
Sign up to see every warm intro you have to Succipro
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Succipro team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Succipro is a biotech spin-off from IRB CatSud and Universitat Rovira i Virgili developing first-in-class drugs that modulate succinate to treat inflammatory bowel disease and metabolic disorders. Its lead program targets inflammatory bowel disease, with additional planned indications in metabolic conditions such as metabolic dysfunction-associated fatty liver.
Investors · 1
Frequently asked questions
- What does Succipro do?
- Succipro is a biotech spin-off from IRB CatSud and Universitat Rovira i Virgili developing first-in-class drugs that modulate succinate to treat inflammatory bowel disease and metabolic disorders. Its lead program targets inflammatory bowel disease, with additional planned indications in metabolic conditions such as metabolic dysfunction-associated fatty liver.
- Who are Succipro's investors?
- Succipro's investors include WA4STEAM.